ANTAGONISTS OF HUMAN INTERLEUKIN-6 THAT ARE TOTALLY INCAPABLE OF BINDING GP 130, AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL COMPOUNDS

Abstract: The present invention relates to antagonists of human interleukin-6 that are totally incapable of binding the receptor chain responsible for transduction of the signal associated with this cytokine, that is to say with gp 130. The figure shows the lack of interaction between human interleukin-6 antagonists according to the invention and the protein gp 130.

Description: ANTAGONISTS OF HUMAN INTERLEUKIN-6 THAT ARE TOTALLY INCAPABLE OF BINDING GP 130, AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL COMPOUNDS DESCRIPTION The present invention relates to antagonists of human interleukin-6 (hIL-6) , that are totally incapable of binding the receptor chain (that is to say with gp 130) responsible for transducing the signal associated with this cytokine. As is known, in known hIL-6 antagonists binding with gp 130 is actually weakened, but not totally abolished. This circumstance may result, in certain cells that are particularly sensitive to the action of the cytokine, in the known hIL-6 antagonists working as weak agonists. For this reason they have no therapeutic use in the formulation of drugs for the treatment of diseases such as multiple myeloma, rheumatoid arthritis, lupus erythematosus and osteoporosis. There is therefore a need in this specific sector for human interleukin-6 antagonists whose use is not associated with the above risk. The use of human interleukin-6 antagonists according to the present invention allows all the problems indicated above to be overcome, and also offers other advantages which will become clear from the following. Subject of the present invention are therefore antagonists of human interleukin-6 (hIL-6) , characterised in that they are totally incapable of binding with gp 130 and consist of an amino acid sequence chosen from the group comprising SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 6 and SEQ ID NO:7. Another subject of the present invention are: isolated and purified molecules of DNA coding for the interleukin-6 antagonists indicated above; recombinant DNA molecules comprising the DNA molecules mentioned above operatively bound to a sequence controlling expression in said recombinant DNA molecules; a unicellular host transformed using the recombinant DNA molecules, the unicellular host being selected from the group comprising bacteria, yeasts and other fungi, animal cells and plant cells. Further subjects of the present invention are the use of human interleukin-6 antagonists of SEQ ID NO: , SEQ ID NO:5, SEQ ID NO: 6 and SEQ ID NO:7 for the preparation of pharmaceutical compounds and the use of said antagonists as active principles in the preparation of drugs for the treatment of multiple myeloma, rheumatoid arthritis, lupus erythematosus and osteoporosis. Up to this point a general description has been given of the present invention. With the aid of the following examples, a more detailed description of a form of embodiment of the invention will now be given, in order to give a clearer understanding of the aims, characteristics, advantages and methods of preparation. Figure 1 shows the absence of interaction between antagonists according to the invention and gp 130. Figure 2 shows the biological antagonism of the antagonists according to the invention compared to wild type interleukin-6 on human hepatoma cells. Figure 3 shows the absence of gpl30 interaction of the mutant Sant 7 according to the present invention. EXAMPLE 1 Generation of interleukin-6 mutants using the method according to the present invention In all the mutagenesis reactions the plasmid pT7.7/lL- 6/DFRD/Hind was used as a template. This plasmid is a derivative from the plasmid pT7.7 (Studier, F. W. and Moffat, B. A., J. Mol . Biol . 189, 113-130, 1986) and contains the coding region of human IL-6 (hIL-6: SEQ ID NO:l) cloned between sites Ndel and Clal of the pT7.7 polylinker. The human IL-6 gene is controlled by the T7 RNA poly erase promoter, present in pT7.7. Mutations were introduced into four codons in the region coding for human IL-6 cloned into pT7.7/IL-6/DFRD/Hind (see SEQ ID NO:l), creating the following amino acid substitutions: Tyr31Asp, Gly35Phe, SerllδArg and Vall21Asp. The published international application No. WO95/00852 by the same Applicant, claiming Italian priority date 20.06.93, teaches that the introduction of the four amino acid substitutions indicated above into wild-type human IL-6 drastically reduces the biological activity of the cytokine modified in this way, without altering its ability to bind to the hIL-6 receptor itself, thus generating IL-6 DFRD (see SEQ ID NO:l), an effective hIL-6 receptor antagonist. Finally, recognition sites for the following restriction enzymes were introduced without these nucleotide substitutions changing the significance of the respective hIL-6 condons at the moment of translation: Sad in the nucleotidic sequence coding amino acids 20-21- 22; Bfrl in the nucleotidic sequence coding amino acids 38- 39-40; Xhol in the nucleotidic sequence coding amino acids 92-93; Hindlll in the nucleotidic sequence coding amino acids 150-151 (see SEQ ID NO:l). A PCR (Polymerase Chain Reaction) strategy was used to generate mutants within the selected codons in the region coding for human interleukin 6. The downstream primer was IL-6 down Not/Cla, a 45 nucleotide primer, corresponding to positions 530-555 (antisense filament) of the cDNA of hIL-6 (taking the first nucleotide of the first codon of the mature polypeptide to be 1). The primer hybridisation site is in the region of hIL-6 cDNA coding for the carboxy-terminal portion of the protein. The primer IL-6 down Not/Cla also contains a recognition site for the restriction enzyme NotI and a recognition site for the restriction enzyme Clal, both downstream of the TAG codon, which encodes the end of protein hIL-6 translation. In the first case, the mutagenetic primer upstream is IL- 6 160R/157WR, a primer with 60 nucleotides having the sequence SEQ ID NO:2. The primer IL-6 160R/157WR extends from position 440 to position 499 (sense filament) of the cDNA of hIL-6 and introduces mutations in the codons coding for the amino acid 157 (tryptophan in wild type hIL-6) and 160 (aspartate in wild type hIL-6) . A DNA fragment of 135 base pairs is amplified using PCR according to standard PCR amplification methods. Amplification is carried out in 35 cycles. Each cycle consists in incubation for 2 minutes at 94°C for denaturation of the template, 2 minutes at 50°C for hybridisation of the oligonucleotide and 3 minutes at 72°C for extension of the chain. The amplified fragment is digested with Hindlll and with Clal and purified on 2% agarose gel. The fragment generated by PCR and digested by the two enzymes is ligated into the vector pT7.7/IL- 6/DFRD/Hind, digested with the same two enzymes, purified on 0.8% agarose gel. In the second case, the mutagenetic upstream primer is IL-6 T162D, a 64 nucleotide primer whose sequence is SEQ ID NO: 3. The primer IL-6 T162D extends from position 441 to position 503 (sense filament) of the cDNA of hIL-6 and introduces mutations in the codons coding for the amino acid 162 (threonine in wild type hIL-6) . A DNA fragment with 134 base pairs is amplified by PCR using standard PCR amplification methods. Amplification is carried out in 35 cycles. Each cycle consists in incubation for 2 minutes at 94°C for denaturation of the template, 2 minutes at 50°C for hybridisation of the oligonucleotide and 3 minutes at 72°C for extension of the chain. The amplified fragment is digested with Hindlll and with Clal and purified on 2% agarose gel. The fragment generated by PCR and digested by the two enzymes is ligated into the vector pT7.7/IL- 6/DFRD/Hind, digested with the same two enzymes, purified on 0.8% agarose gel. The identity of the mutants obtained from both PCR reactions was verified by sequence analysis of single isolates. The amino acid substitutions found in the mutant IL-6 DFRD/D160R are described in SEQ ID NO:4, the amino acid substitutions found in the mutant IL-6 DFRD/W157R/D160R are described in SEQ ID NO:5 and the amino acid substitutions found in the mutant IL-6 DFRD/T162D are described in SEQ ID NO: 6. EXAMPLE 2 Demonstration that binding of the antagonists according to the invention to the specific receptor is unchanged with respect to wild type interleukin-6 The proteins IL-6 DFRD/D160R (coded by the cDNA described in SEQ ID NO:4), IL-6 DFRD/W157R/D160R (coded by the cDNA described in SEQ ID NO:5) and IL-6 DFRD/T162D (coded by the cDNA described in SEQ ID NO: 6) were produced according to the state of the art, as described (Arcone, R., Pucci, P., Zappacosta, F., Fontaine, V., Malorni, A., Marino, G., and Ciliberto, G., Eur. J. Bioche . 198, 541-547, 1991) . The ability of the mutants to bind to the hIL-6 receptor was measured using state of the art methods, as described (Savino, R., Lahm, A., Salvati, A.L., Ciapponi, L., Sporeno, E., Altamura, S., Paonessa, G., Toniatti, C, Ciliberto, G., EMBO J. 13, 1357-1367, 1994) . Table 1 below gives the receptor binding levels for wild type IL-6 and for the mutant forms obtained as described in example 1. TABLE 1 Ability of the mutants obtained as described in example 1 to bind to the IL-6e receptor Wild type IL-6 100% IL-6 DFRD/D160R (SEQ ID NO:4) 137% IL-6 DFRD/W157R/D160R (SEQ ID NO:5) 130% IL-6 DFRD/T162D (SEQ ID NO:6) 39% EXAMPLE 3 Demonstration of the fact that the antagonists according to the invention are totally incapable of binding gp 130 The mutants IL-6 DFRD (coded by the cDNA described in SEQ ID NO:l), IL-6 DFRD/W157R/D160R (coded by the cDNA described in SEQ ID NO:5) and IL-6 DFRD/T162D (coded by the cDNA described in SEQ ID NO: 6) were tested for their ability to bind gpl30. For this purpose the experimental system used is represented by a series of immunoprecipitations in the presence of the two receptor components: the specific IL-6Rα receptor and the transducing sub-unit gpl30. These two receptors were produced in insect cells using the expression system known as Baculovirus. Both IL-6Rα and gpl30 were expressed as soluble molecules (indicated by the prefix s before the name of the receptor, for example sgpl30 or sIL- 6Rα) , that is to say without the membrane and intra- cytoplasmatic domains. Furthermore, in the case of gpl30, several amino acids representing the recognition sites (epitopes) for specific monoclonal antibodies were added before the COOH terminus, immediately before the stop codon. Two types of epitopes were added, known as " yc" (made up of 10 amino acids) and "FLAG" (made up of 8 amino acids) , so as to generate two types of molecule: sgpl30-myc and sgpl30- FLAG. Likewise, two types of receptor were generated for sIL- 6Rα, one without any addition, known as sIL-6Rα, and another with the epitope tag myc, known as sIL-6Rα-myc. These recombinant receptors were produced in insect cells (denominated High Five) as soluble molecules and then secreted into the cell culture medium. The use of a culture medium containing methionine labelled with radioactive sulphur ( 35 S) allowed production of radioactive receptors which were used in the experiments. The wild type IL-6 and the mutants were produced according to the state of the art, as described (Arcone, R., Pucci, P., Zappacosta, F., Fontaine, V., Malorni, A., Marino, G., and Ciliberto, G., Eur. J. Biochem 198, 541-547, 1991). The first assay to determine binding of the IL-6 mutants to gpl30, known as the gpl30 direct binding assay, was carried out as follows. The receptor sIL-6Rα-myc was immobilised on protein A Sepharose beads by means of the anti-myc monoclonal antibody, and incubated with IL-6 or with the above mentioned mutants in the presence of sgpl30-FLAG labelled with 35 S. As the latter molecule is not immunoprecipitated by the anti-myc antibody, its immunoprecipitation can only be explained by assuming direct binding to the IL-6/sIL-6Rα-myc complex formed on the beads. After incubation, the beads (with the immobilised complexes) were washed to eliminate excess unbound 35 S-sgpl30-FLAG. The beads were then incubated with a solution containing SDS in which the proteins were denatured and the receptor complex formed was dissociated. The whole was then loaded onto SDS- polyacrylamide gel with which it is possible to evaluate the - 7 - amount of bound ' 5 S-sgpl30-FLAG and therefore the ability of the IL-6 mutants to bind gpl30. As can be seen in the right hand part of figure 1 (under the heading "Direct binding to gpl30") in this type of assay the mutant IL-6 DFRD is still capable of binding gpl30. On the contrary, the mutants DFRD/W157R/D160R and DFRD/T162D are completely incapable of binding gpl30. The second gpl30 binding assay has the aim of testing the ability of the mutants to form a receptor complex in which gpl30 is present as a dimer. The gpl30 dimer is closely related to the ability of the receptor complex to transduce the signal inside the cell. This assay was carried out by immobilising sgpl30-myc on Sepharose beads (again using the anti-myc monoclonal antibody) and incubating it with IL-6 (wild type or mutant) in the presence of sIL-6Rα and 35S- sgpl30-FLAG. As in the preceding assay, the latter molecule cannot be immunoprecipitated by the anti-myc antibody, and its immunoprecipitation can only be explained by assuming the formation of a receptor complex with the sgpl30-myc present on the beads. In this case, after the incubation period and the subsequent washing (to eliminate any excess of 35S- sgpl30-FLAG) , the presence of 35S-sgpl30-FLAG in the receptor complex indicates the formation of a gpl30 dimer. As in the preceding case, the beads were then incubated with a solution containing SDS in which the proteins were denatured and the receptor complex formed was dissociated. The whole was then loaded onto SDS-polyacrylamide gel, from which it was possible to evaluate the amount of bound 35S-sgpl30-FLAG and therefore the ability of the IL-6 mutants to induce formation of a gpl30 dimer. As can be seen in the left hand section of figure 1 (under the heading "gpl30 Di erisation") , in this case only wild type IL-6 was capable of inducing the formation of the gpl30 dimer. The result confirms that none of the mutants is capable of dimerising gpl30 and therefore of forming a receptor complex in which two molecules of gpl30 can trigger the signal within the cell. EXAMPLE 4 Demonstration that the proteins modified according to the present invention are functional antagonists of human interleukin 6 in hepatoma cells The proteins IL-6 DFRD/W157R/D160R (coded by the cDNA described in SEQ ID NO:5) and IL-6 DFRD/T162D (coded by the cDNA described in SEQ ID NO: 6) were selected for analysis of agonistic activity. The biological activity of the two mutants on human hepatoma cells was measured according to the state of the art, as described (Gregory, B., Savino, R. and Ciliberto, G., J. Immunol . Methods, 170, 47-56, 1994). Table 2 below indicates the values for biological activity of wild type IL-6 and for the two mutant forms obtained as described in example 1. TABLE 2 Biological activity of IL-6 and of the mutants obtained as described in example 1 Wild type IL-6 100% IL-6 DFRD/W157R/D160R (SEQ ID NO:5) 0% IL-6 DFRD/T162D (SEQ ID NO:6) 0% The two variants IL-6 DFRD/W157R/D160R (SEQ ID NO:5) and IL-6 DFRD/T162D (SEQ ID NO: 6) show no sign of biological activity in human hepatoma cells, they still have the ability to bind the receptor gp80, but have completely lost the ability to bind gpl30, as described in example 3. They were therefore used in competition tests on the biological activity of wild type interleukin 6 in human hepatoma cells. The cells were stimulated with wild type interleukin 6 at 4 nanogrammes per millilitre (ng/ml) of culture medium, in the presence of increasing concentrations of the two mutants. As illustrated in figure 2 (in which the biological activity of wild type interleukin 6 is expressed in arbitrary units), increasing concentrations of the mutant are capable of efficiently antagonising the effects of wild type interleukin 6 on the human hepatoma cells. Example 5 Generation of a further interleukin-6 mutant using the method according to the present invention, demonstration of the fact that it is totally incapable of binding gp!30 and that is a functional antagonist of human interleukin-6. As already mentioned in Example 1, publication WO95/00852 by the same Applicant, claiming Italian priority date 20.06.93, teaches that the introduction of the four amino acid substitutions Tyr31Asp, Gly35Phe, SerllδArg and Vall21Asp into wild-type human IL-6 drastically reduces the biological activity of the cytokine modified in this way, without altering its ability to bind to the hIL-6 receptor itself, thus generating IL-6 DFRD (see SEQ ID NO:l), an effective hIL-6 receptor antagonist. Moreover, example 3 above has shown that IL-6 DFRD, although unable to dimerize gpl30, is still capable of binding gpl30 itself. The international patent application PCT/IT95/00216 filed by the same Applicant 13.12.95, claiming Italian priority 14.12.94, describes that the introduction of the five amino acid substitutions Gln75Tyr, Ser76Lys, Glnl75Ile, Serl76Arg and Glnl83Ala into IL-6 DFRD strongly increases its ability to bind to the hIL-6 receptor and decreases the amount of protein necessary to inhibit wild-type hIL-6 activity on both human hepatoma and on human myeloma cells, thus generating Sant5, a much more potent hIL-6 receptor antagonists. Using the Polymerase Chain Reaction (PCR) molecular biology technique, the three amino acid substitutions Leu57Asp, Glu59Phe and Asn60Trp were inserted into Sant5 thus generating mutant protein Sant7, whose amino acid substitutions are described in SEQ ID NO:7. The mutant protein Sant7 was produced according to the state of the art, as described (Arcone, R., Pucci, P., Zappacosta, F., Fontaine, V., Malorni, A., Marino, G., Ciliberto, G., Eur. J. Biochem. 198, 541-547, 1991) . The ability of Sant7 to bind to the hIL-6 receptor was measured using the state of the art methods, as described (Savino, R., Lahm, A., Salvati, A.L., Ciapponi, L., Sporeno, E., Altamura, -10- S., Paonessa, G., Toniatti, C, Ciliberto, G., EMBO J. 13, 1357-1367, 1994) . Table 3 below gives the receptor binding capacity for wild type IL-6 and for Sant7. TABLE 3 Ability of Sant7to bind the IL-6 receptor (% of the wild-type IL-6) Wild type IL-6 100% Sant7 6500% As can be seen from the table, also Sant7, like the parental mutant Sant5 (as described in PCT patent application number IT9500216 filed by the same Applicant 13.12.95), has a binding capacity for the specific IL-6 receptor increased with respect to wild-type IL-6. The ability of Sant7 in binding to gpl30 was tested with the same techniques described in the example 3. As can be seen in the right hand part of figure 3 (under the heading "Direct binding to gpl30) in this type of assay the mutant Sant7 is completely uncapable of binding gpl30 (unlike the parental mutant DFRD) . The ability of Sant7 to form a receptor complex in wich gpl30 is present as a dimer was also tested with the same tecnique described in the example 3. As can be seen in the left hand part of figure 3 (under the heading "gpl30 Dimerisation") , only wild-type IL-6 is capable of inducing the formation of the gpl30 dimer, therefore Sant7 is not able to form a receptor complex in which two molecules of gpl30 can trigger the signal inside the cell. The ability of Sant7 to inhibit wild-type hIL-6 biological activity was tested on Hep3B human hepatoma cells, according to the state of the art, as described (Savino, R., Lah , A., Salvati, A.L., Ciapponi, L., Sporeno, E., Altamura, S., Paonessa, G., Toniatti, C, Ciliberto, G., EMBO J. 13, 1357-1367, 1994) . We also tested the ability of Sant7 to fully inhibit the interleukin 6-dependent growth of two human myeloma cell line, called XG-1 and XG-2, derived from freshly isolated myeloma cells from patients with terminal disease. The XG-1 and XG-2 myeloma cell lines growth is dependent on exogenously added interleukin 6, similarly to what has been shown for fresh myeloma cells, therefore these cell lines can be considered an excellent in vi tro model of the multiple myeloma disease (Jourdan, M., Zhang, X-G., Portier, M., Boiron, J.-M., Bataille, R. and Klein, B. (1991) J. Immunol. 147, 4402-4407) . Table 4 show the concentrations of Sant7 (expressed in nanograms of mutant per milliliter of colture medium) necessary to inhibit 90% of interleukin 6 biological activity (hepatoma cells were stimulated with 4 nanograms of wild type interleukin 6 per milliliter of colture medium, while XG-1 myeloma cells were stimulated with 0.1 nanograms and XG-2 with 0.5 nanograms of interleukin 6 per milliliter of colture medium, due to the higher sensitivity of the latter cells to wild type interleukin 6) . TABLE 4 Inhibition of wild-type interleukin-6 biological activity by Sant7 on both hepatoma and myeloma cells. hIL-6 90% inhibition of interleukin-6 acivity on Mutant hepatoma cells myeloma cells Hep3B XG-1 XG-2 Sant7 30 ng/ml 35 ng/ml 950 ng/ml As can be seen from the table, Sant7 behaves as a very effective interleukin-6 receptor antagonist on all cell lines tested. SEQUENCE LISTING GENERAL INFORMATION (i) APPLICANT: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A. et al. (ii) TITLE OF INVENTION: ANTAGONISTS OF HUMAN INTERLEUKIN-6 THAT ARE TOTALLY INCAPABLE OF BINDING GP 130, AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL COMPOUNDS (iii) NUMBER OF SEQUENCES: 7 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk 3.5" 1.44 MBYTES (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (R) 6.22 (D) SOFTWARE: Microsoft Word for Windows 6.0 (v) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Societa Italiana Brevetti (B) STREET: Piazza di Pietra, 39 (C) CITY: Rome (D) COUNTRY: Italy (E) POSTAL CODE: 1-00186 (viii) ATTORNEY INFORMATION (A) NAME: DI CERBO, Mario (Dr.) (B) REFERENCE: RM/X88529/PC-DC (ix) TELECOMMUNICATION INFORMATION (A) TELEPHONE: 06/6785941 (B) TELEFAX: 06/6794692 (C) TELEX: 612287 ROPAT (1) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS (A) LENGTH: 555 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: no (iv) ANTISENSE: no (v) FRAGMENT TYPE: internal (vii) IMMEDIATE SOURCE: (A) SYNTHESIS: production in E.coli K12 (ix) FEATURES: (A) NAME: pT7.7/IL-6/DFRD/Hind (C) IDENTIFICATION METHOD: polyacrylamide gel (xi ) SEQUENCE DESCRI PTION : SEQ ID NO : 1 : CCA GTA CCC CCA GGA GAA GAT TCC AAA GAT GTA GCC GCC CCA CAC AGA 48 Pro Val Pro Pro Gly Glu Asp Ser L s Asp Val Ala Ala Pro His Arg 1 5 10 15 CAG CCA CTC ACG AGC TCA GAA CGA ATT GAC AAA CAA ATT CGG GAC ATC 96 Gin Pro Leu Thr Ser Ser Glu Arg lie Asp Lys Gin He Arg Asp He 20 25 30 CTC GAC TTT ATC TCA GCC TTA AGA AAG GAG ACA TGT AAC AAG AGT AAC 144 Leu Asp Phe He Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys Ser Asn 35 40 45 ATG TGT GAA AGC AGC AAA GAG GCA CTG GCA GAA AAC AAC CTG AAC CTT 192 Met Cys Glu Ser Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu 50 55 60 CCA AAG ATG GCT GAA AAA GAT GGA TGC TTC CAA TCT GGA TTC AAT GAG 240 Pro Lys Met Ala Glu Lys Asp Gly Cys Phe Gin Ser Gly Phe Asn Glu 65 70 75 80 GAG ACT TGC CTG GTG AAA ATC ATC ACT GGT CTT CTC GAG TTT GAG GTA 288 Glu Thr Cys Leu Val Lys He He Thr Gly Leu Leu Glu Phe Glu Val 85 90 95 TAC CTA GAG TAC CTC CAG AAC AGA TTT GAG AGT AGT GAG GAA CAA GCC 336 Tyr Leu Glu Tyr Leu Gin Asn Arg Phe Glu Ser Ser Glu Glu Gin Ala 100 105 110 AGA GCT GTC CAG ATG CGC ACA AAA GAC CTG ATC CAG TTC CTG CAG AAA 384 Arg Ala Val Gin Met Arg Thr Lys Asp Leu He Gin Phe Leu Gin Lys 115 120 125 AAG GCA AAG AAT CTA GAT GCA ATA ACC ACC CCT GAC CCA ACC ACA AAT 432 Lys Ala Lys Asn Leu Asp Ala He Thr Thr Pro Asp Pro Thr Thr Asn 130 135 140 GCC AGC CTG CTG ACG AAG CTT CAG GCA CAG AAC CAG TGG CTG CAG GAC 480 Ala Ser Leu Leu Thr Lys Leu Gin Ala Gin Asn Gin Tip Leu Gin Asp 145 150 155 160 ATA ACA ACT CAT CTC ATT CTG CGC AGC TTT AAG GAG TTC CTG CAG TCC 528 Met Thr Thr His Leu He Leu Arg Ser Phe Lys Glu Phe Leu Gin Ser 165 170 175 AGC CTG AGG GCT CTT CGG CAA ATG TAG 555 Ser Leu Arg Ala Leu Arg Gin Met 180 (2) INFORMATION FOR SEQ ID NO: 2 (i) SEQUENCE CHARACTERISTICS (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: synthetic DNA (iii) HYPOTHETICAL: no (iv) ANTISENSE: no (v) FRAGMENT TYPE: internal (vii) IMMEDIATE SOURCE: (A) SYNTHESIS: oligonucleotide synthesizer (ix) FEATURES: (A) NAME: IL-6 160R/157WR (C) IDENTIFICATION METHOD: polyacrylamide gel (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: -15- CGCTGACGAA GCTTCAGGCA CAGAACCAGY GGCTGCAGCG TATGACAACT GATCTCATTC 60 In which Y may be a base chosen from between C and T (3) INFORMATION FOR SEQ ID NO: 3 (i) SEQUENCE CHARACTERISTICS (A) LENGTH: 64 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: synthetic DNA (iii) HYPOTHETICAL: no (iv) ANTISENSE: no (v) FRAGMENT TYPE: internal (vii) IMMEDIATE SOURCE: (A) SYNTHESIS: oligonucleotide synthesizer (ix) FEATURES: (A) NAME: IL-6 T162D (C) IDENTIFICATION METHOD: polyacrylamide gel (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: GCTGACGAAG CTTCAGGCAC AGAACCAGTG GCTGCAGGAC ATGGACACTC ATCTCATTCT 60 GCGC 64 (4) INFORMATION FOR SEQ ID NO: 4 (i) SEQUENCE CHARACTERISTICS (A) LENGTH: 555 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: no (iv) ANTISENSE: no (v) FRAGMENT TYPE: internal (vii) IMMEDIATE SOURCE: (A) SYNTHESIS: production in E.coli K12 (ix) FEATURES: (A) NAME: IL-6 DFRD/D160R ( C ) I DENT I FICAT ION METHOD : po l yac ryl amide gel ( xi ) SEQUENCE DESCRI PT I ON : SEQ I D NO : 4 : CCA GTA CCC CCA GGA GAA GAT TCC AAA GAT GTA GCC GCC CCA CAC AGA 48 Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg 1 5 10 15 CAG CCA CTC ACG AGC TCA GAA CGA ATT GAC AAA CAA ATT CGG GAC ATC 96 Gin Pro Leu Thr Ser Ser Glu Arg He Asp Lys Gin He Arg Asp He 20 25 30 CTC GAC TTT ATC TCA GCC TTA AGA AAG GAG ACA TGT AAC AAG AGT AAC 144 Leu Asp Phe He Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys Ser Asn 35 40 45 ATG TGT GAA AGC AGC AAA GAG GCA CTG GCA GAA AAC AAC CTG AAC CTT 192 Met Cys Glu Ser Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu 50 55 60 CCA AAG ATG GCT GAA AAA GAT GGA TGC TTC CAA TCT GGA TTC AAT GAG 240 Pro Lys Met Ala Glu Lys Asp Gly Cys Phe Gin Ser Gly Phe Asn Glu 65 70 75 80 GAG ACT TGC CTG GTG AAA ATC ATC ACT GGT CTT CTC GAG TTT GAG GTA 288 Glu Thr Cys Leu Val Lys He He Thr Gly Leu Leu Glu Phe Glu Val 85 90 95 TAC CTA GAG TAC CTC CAG AAC AGA TTT GAG AGT AGT GAG GAA CAA GCC 336 Tyr Leu Glu Tyr Leu Gin Asn Arg Phe Glu Ser Ser Glu Glu Gin Ala 100 105 1 10 AGA GCT GTC CAG ATG CGC ACA AAA GAC CTG ATC CAG TTC CTG CAG AAA 384 Arg Ala Val Gin Met Arg Thr Lys Asp Leu He Gin Phe Leu Gin Lys 115 120 125 AAG GCA AAG AAT CTA GAT GCA ATA ACC ACC CCT GAC CCA ACC ACA AAT 432 Lys Ala Lys Asn Leu Asp Ala He Thr Thr Pro Asp Pro Thr Thr Asn 130 135 140 GCC AGC CTG CTG ACG AAG CTT CAG GCA CAG AAC CAG TGG CTG CAG GAC 480 Ala Ser Leu Leu Thr Lys Leu Gin Ala Gin Asn Gin Trp Leu Gin Arg 145 150 155 160 ATA ACA ACT CAT CTC ATT CTG CGC AGC TTT AAG GAG TTC CTG CAG TCC 528 Met Thr Thr His Leu He Leu Arg Ser Phe Lys Glu Phe Leu Gin Ser 165 170 175 AGC CTG AGG GCT CTT CGG CAA ATG TAG 555 Ser Leu Arg Ala Leu Arg Gin Met 180 (5) INFORMATION FOR SEQ ID NO: 5 (i) SEQUENCE CHARACTERISTICS (A) LENGTH: 555 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: no (iv) ANTISENSE: no (v) FRAGMENT TYPE: internal (vii) IMMEDIATE SOURCE: (A) SYNTHESIS: production in E.coli K12 (ix) FEATURES: (A) NAME: IL-6 DFRD/W157R/D160R (C) IDENTIFICATION METHOD: polyacrylamide gel (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: CCA GTA CCC CCA GGA GAA GAT TCC AAA GAT GTA GCC GCC CCA CAC AGA 48 Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg 1 5 10 15 CAG CCA CTC ACG AGC TCA GAA CGA ATT GAC AAA CAA ATT CGG GAC ATC 96 Gin Pro Leu Thr Ser Ser Glu Arg He Asp Lys Gin He Arg Asp He 20 25 30 CTC GAC TTT ATC TCA GCC TTA AGA AAG GAG ACA TGT AAC AAG AGT AAC 144 Leu Asp Phe He Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys Ser Asn 35 40 45 ATG TGT GAA AGC AGC AAA GAG GCA CTG GCA GAA AAC AAC CTG AAC CTT 192 Met Cys Glu Ser Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu 50 55 60 CCA AAG ATG GCT GAA AAA GAT GGA TGC TTC CAA TCT GGA TTC AAT GAG 240 Pro Lys Met Ala Glu Lys Asp Gly Cys Phe Gin Ser Gly Phe Asn Glu 65 70 75 80 GAG ACT TGC CTG GTG AAA ATC ATC ACT GGT CTT CTC GAG TTT GAG GTA 288 Glu Thr Cys Leu Val Lys He He Thr Gly Leu Leu Glu Phe Glu Val 85 90 95 TAC CTA GAG TAC CTC CAG AAC AGA TTT GAG AGT AGT GAG GAA CAA GCC 336 Tyr Leu Glu Tyr Leu Gin Asn Arg Phe Glu Ser Ser Glu Glu Gin Ala 100 105 110 AGA GCT GTC CAG ATG CGC ACA AAA GAC CTG ATC CAG TTC CTG CAG AAA 384 Arg Ala Val Gin Met Arg Thr Lys Asp Leu He Gin Phe Leu Gin Lys 115 120 125 AAG GCA AAG AAT CTA GAT GCA ATA ACC ACC CCT GAC CCA ACC ACA AAT 432 Lys Ala Lys Asn Leu Asp Ala He Thr Thr Pro Asp Pro Thr Thr Asn 130 135 140 GCC AGC CTG CTG ACG AAG CTT CAG GCA CAG AAC CAG TGG CTG CAG GAC 480 Ala Ser Leu Leu Thr Lys Leu Gin Ala Gin Asn Gin Arg Leu Gin Arg 145 150 155 160 ATA ACA ACT CAT CTC ATT CTG CGC AGC TTT AAG GAG TTC CTG CAG TCC 528 Met Thr Thr His Leu He Leu Arg Ser Phe Lys Glu Phe Leu Gin Ser 165 170 175 AGC CTG AGG GCT CTT CGG CAA ATG TAG 555 Ser Leu Arg Ala Leu Arg Gin Met 180 (6) INFORMATION FOR SEQ ID NO: 6 (i) SEQUENCE CHARACTERISTICS (A) LENGTH: 555 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: no (iv) ANTISENSE: no (v) FRAGMENT TYPE: internal (vii) IMMEDIATE SOURCE: (A) SYNTHESIS: production in E.coli K12 (ix) FEATURES: (A) NAME: IL-6 DFRD/T162D (C) IDENTIFICATION METHOD: polyacrylamide gel (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: CCA GTA CCC CCA GGA GAA GAT TCC AAA GAT GTA GCC GCC CCA CAC AGA 48 Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg 1 5 10 15 CAG CCA CTC ACG AGC TCA GAA CGA ATT GAC AAA CAA ATT CGG GAC ATC 96 Gin Pro Leu Thr Ser Ser Glu Arg He Asp Lys Gin He Arg Asp He 20 25 30 CTC GAC TTT ATC TCA GCC TTA AGA AAG GAG ACA TGT AAC AAG AGT AAC 144 Leu Asp Phe He Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys Ser Asn 35 40 45 ATG TGT GAA AGC AGC AAA GAG GCA CTG GCA GAA AAC AAC CTG AAC CTT 192 Met Cys Glu Ser Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu 50 55 60 CCA AAG ATG GCT GAA AAA GAT GGA TGC TTC CAA TCT GGA TTC AAT GAG 240 Pro Lys Met Ala Glu Lys Asp Gly Cys Phe Gin Ser Gly Phe Asn Glu 65 70 75 80 GAG ACT TGC CTG GTG AAA ATC ATC ACT GGT CTT CTC GAG TTT GAG GTA 288 Glu Thr Cys Leu Val Lys He He Thr Gly Leu Leu Glu Phe Glu Val 85 90 95 TAC CTA GAG TAC CTC CAG AAC AGA TTT GAG AGT AGT GAG GAA CAA GCC 336 Tyr Leu Glu Tyr Leu Gin Asn Arg Phe Glu Ser Ser Glu Glu Gin Ala 100 105 110 AGA GCT GTC CAG ATG CGC ACA AAA GAC CTG ATC CAG TTC CTG CAG AAA 384 Arg Ala Val Gin Met Arg Thr Lys Asp Leu He Gin Phe Leu Gin Lys 115 120 125 AAG GCA AAG AAT CTA GAT GCA ATA ACC ACC CCT GAC CCA ACC ACA AAT 432 Lys Ala Lys Asn Leu Asp Ala He Thr Thr Pro Asp Pro Thr Thr Asn 130 135 140 GCC AGC CTG CTG ACG AAG CTT CAG GCA CAG AAC CAG TGG CTG CAG GAC 480 Ala Ser Leu Leu Thr Lys Leu Gin Ala Gin Asn Gin Tip Leu Gin Asp 145 150 155 160 ATA ACA ACT CAT CTC ATT CTG CGC AGC TTT AAG GAG TTC CTG CAG TCC 528 Met Asp Thr His Leu He Leu Arg Ser Phe Lys Glu Phe Leu Gin Ser 165 170 175 AGC CTG AGG GCT CTT CGG CAA ATG TAG 555 Ser Leu Arg Ala Leu Arg Gin Met 180 (7) INFORMATION FOR SEQ ID NO: 7 (i) SEQUENCE CHARACTERISTICS -21- (A) LENGTH: 555 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: no (iv) ANTISENSE: yes (v) FRAGMENT TYPE: internal (vii) IMMEDIATE SOURCE (A) SYNTHESIS: production in E. coli K12 (ix) FURTHER CHARACTERISTICS (A) NAME : Sant7 (C) IDENTIFICATION METHOD: polyacrylamide gel (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: CCA GTA CCC CCA GGA GAA GAT TCC AAA GAT GTA GCC GCC CCA CAC AGA 48 Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg 1 5 10 15 CAG CCA CTC ACG AGC TCA GAA CGA ATT GAC AAA CAA ATT CGG GAC ATC 96 Gin Pro Leu Thr Ser Ser Glu Arg He Asp Lys Gin He Arg Asp He 20 25 30 CTC GAC TTT ATC TCA GCC TTA AGA AAG GAG ACA TGT AAC AAG AGT AAC 144 Leu Asp Phe He Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys Ser Asn 35 40 45 ATG TGT GAA AGC AGC AAA GAG GCC GAC GCA TTC TGG AAC CTG AAC CTT 192 Met Cys Glu Ser Ser Lys Glu Ala Asp Ala Phe Tip Asn Leu Asn Leu 50 55 60 CCA AAG ATG GCT GAA AAA GAC GGA TGC TTC TAC AAA GGA TTC AAT GAG 240 Pro Lys Met Ala Glu Lys Asp Gly Cys Phe Tyr Lys Gly Phe Asn Glu 65 70 75 80 GAG ACT TGC CTG GTG AAA ATC ATC ACT GGT CTT TTC GAG TTT GAG GTA 288 Glu Thr Cys Leu Val Lys He He Thr Gly Leu Leu Glu Phe Glu Val 85 90 95 TAC CTA GAG TAC CTC CAG AAC AGA TTT GAG AGT AGT GAG GAA CAA GCC 336 Tyr Leu Glu Tyr Leu Gin Asn Arg Phe Glu Ser Ser Glu Glu Gin Ala 100 105 110 AGA GCT GTC CAG ATG CGC ACA AAA GAC CTG ATC CAG TTC CTG CAG AAA 384 Arg Ala Val Gin Met Arg Thr Lys Asp Leu He Gin Phe Leu Gin Lys 115 120 125 AAG GCA AAG AAT CTA GAT GCA ATA ACC ACC CCT GAC CCA ACC ACA AAT 432 Lys Ala Lys Asn Leu Asp Ala He Thr Thr Pro Asp Pro Thr Thr Asn 130 135 140 GCC AGC CTG CTG ACG AAG CTG CAG GCA CAG AAC CAG TGG CTG CAG GAC 480 Ala Ser Leu Leu Thr Lys Leu Gin Ala Gin Asn Gin Trp Leu Gin Asp 145 150 155 160 ATG ACA ACT CAT CTC ATT CTG CGC AGC TTT AAG GAG TTC CTG AUC CGT 528 Met Thr Thr His Leu He Leu Arg Ser Phe Lys Glu Phe Leu He Arg 165 170 175 AGC CTG AGG GCT CTT CGG GCT ATG TAG 555 Ser Leu Arg Ala Leu Arg Ala Met 180

Claims: CLAIMS 1. Human interleukin-6 (hIL-6) antagonists, characterized in that they are totally incapable of binding gp 130 and in that they consist of an amino acid sequence selected from the group comprising SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 6 and SEQ ID NO:7. 2 . Isolated and purified DNA molecules coding for the antagonists of human interleukin-6 according to claim 1. 3. Recombinant DNA molecules comprising DNA molecules according to claim 2 operatively bound to a sequence controlling expression of recombinant DNA in said molecules. 4. A unicellular host transformed using a recombinant DNA molecule according to claim 3. 5. A unicellular host according to claim 4, selected from the group comprising bacteria, yeasts and other fungi, animal and plant cells. 6. Use of SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 6 and SEQ ID NO: for the preparation of pharmaceutical compounds. 7. Use of SEQ ID NO: , SEQ ID NO:5, SEQ ID NO: 6 and SEQ ID NO:7 as active principles in the preparation of drugs for the treatment of multiple myeloma, rheumatoid arthritis, lupus erythematosus and osteoporosis. 8. Human interleukin-6 anatagonists totally incapable of binding gp 130, molecules of DNA coding for these antagonists and molecules of recombinant DNA comprising the DNA coding for these antagonists and use of said antagonists for the preparation of pharmaceutical compositions for the treatment of multiple myeloma, rheumatoid arthritis, lupus erythematosus and osteoporosis as described, illustrated and claimed above.

Inventors: CILIBERTO GENNARO, PAONESSA GIACOMO, SAVINO ROCCO, CILIBERTO, GENNARO, PAONESSA, GIACOMO, SAVINO, ROCCO
Applicants: ANGELETTI P IST RICHERCHE BIO, CILIBERTO GENNARO, PAONESSA GIACOMO, SAVINO ROCCO, CILIBERTO, GENNARO, ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANG, PAONESSA, GIACOMO, SAVINO, ROCCO
Application year: 1996
Main classification: C12N15
IPC codes: A61K38, A61K48, A61P3, A61P19, A61P29, A61P35, A61P37, A61P43, C07K14, C12N1, C12N5, C12N15, C12P21